Research library

A

grade

Orforglipron demonstrated non-inferiority to insulin glargine for cardiovascular safety in adults with type 2 diabetes, but gastrointestinal side effects were common.

HR 0.84; 95% CI 0.59-1.20; p<0.0001 for non-inferiority.

summary

B

grade

Not reported in abstract.

summary

A

grade

Relaxin may improve dyspnoea and reduce hospital stay in patients with acute heart failure, but further studies are needed to confirm these findings.

40% of patients in the relaxin 30 microg/kg group moderately or markedly improved dyspnoea at 6 h, 12 h, and 24 h vs 23% in the placebo group, p=0.044.

summary

A

grade

Serelaxin improved dyspnoea relief in patients with acute heart failure, but did not significantly affect readmission rates or cardiovascular death.

VAS AUC improvement of 448 mm × h, 95% CI 120-775; p=0·007 for serelaxin vs placebo.

summary

A

grade

Serelaxin did not show a significant benefit over placebo in reducing cardiovascular death or worsening heart failure in hospitalized patients with acute heart failure.

Hazard ratio for death from cardiovascular causes was 0.98; 95% CI, 0.83 to 1.15; P = 0.77.

summary

B

grade

The study found that young men had a significantly greater GH response to GHRH and GHRP-2 compared to older men, with abdominal fat negatively impacting GH release.

1.4-fold more GH release with l-arginine/GHRH in young than older men, P = 0.021.

summary

A

grade

This study found that gender and sex-steroid supplementation significantly affect growth hormone recovery from autoinhibition, with distinct effects based on the type of secretagogue used.

Nadir GH and peak GH during feedback were enhanced by GHRH or GHRP-2 (P < 0.001 for both).

summary

B

grade

Eliminating senescent pulmonary endothelial cells may worsen pulmonary hemodynamics, challenging the notion that senolytic therapies are universally beneficial.

Not reported in abstract.

summary

A

grade

Pemvidutide showed a significant improvement in MASH resolution at 24 weeks compared to placebo, but did not demonstrate significant fibrosis improvement.

MASH resolution without fibrosis worsening: 58% in 1.2 mg pemvidutide group, p<0.0001.

summary

A

grade

Not reported in abstract.

summary

B

grade

The study provides system-specific reference intervals for serum hCG in postmenopausal women, which may help reduce misclassification of hCG elevations.

97.5th percentile RIs were < 7.1, < 8.2, < 5.7, and < 5.9 IU/L for Systems A-D.

summary

B

grade

Low PAPP-A and PlGF levels, along with elevated AFP, may indicate a higher risk for pre-eclampsia in the first trimester, but further validation is necessary before clinical application.

AUC of 0.94 (95% CI 0.89–0.97) for the combination of AFP, PAPP-A, and PlGF.

summary

B

grade

Efgartigimod may improve perioperative outcomes in gMG patients with thymoma, but further studies are needed to confirm these findings.

Not reported in abstract.

summary

B

grade

Efgartigimod may induce a partial response in refractory ITP, which can be enhanced by TPO-RAs, leading to sustained remission.

Not reported in abstract.

summary

B

grade

Not reported in abstract.

summary

B

grade

Diet-induced fasting ghrelin elevation may indicate recovery of insulin sensitivity and reduction in visceral fat, especially in men.

FGL increased by 10.5% in the green-MED group, P = 0.03 for green-MED vs HDG.

summary

B

grade

Not reported in abstract.

summary

B

grade

Glucocorticoids inhibit growth hormone release by enhancing beta-adrenergic responsiveness, with significant effects observed in a controlled study of normal volunteers.

GH peak: 10.7 +/- 3.9 vs. 20.3 +/- 5.5 micrograms/L; DEX vs. P study, respectively, P < 0.05.

summary

A

grade

CJC-1295 administration resulted in sustained increases in GH and IGF-I levels in healthy adults without serious adverse reactions.

Mean plasma GH concentrations increased by 2- to 10-fold for 6 d or more.

summary

B

grade

CJC-1295 significantly increases basal and mean GH levels and IGF-I production while preserving GH pulsatility, but the clinical implications of these changes remain unclear.

7.5-fold increase in basal GH levels, P < 0.0001.

summary

A

grade

The study suggests that higher doses of efpeglenatide may lead to better cardiovascular outcomes, but the clinical significance of lower doses remains uncertain.

MACE occurred in 125 (9.2%) participants assigned to placebo, 84 (6.2%) participants assigned to 6 mg of efpeglenatide, HR 0.65 (95% CI, 0.5-0.86), P=0.0027.

summary

B

grade

Changes in LDL cholesterol and UACR may explain some of efpeglenatide's effect on reducing major cardiovascular events, but the contributions are modest.

27% reduction in major cardiovascular events compared to placebo during a median follow-up of 1.81 years, n=4076.

summary

B

grade

Desmopressin shows a clinical response in about 60% of children with nocturnal enuresis, but one-third may relapse after treatment. Factors like age and medical history can influence outcomes.

Complete response observed in 346 patients (60.1%) at 3-month follow-up.

summary

B

grade

This case emphasizes the importance of investigating the underlying causes of arginine vasopressin deficiency, as timely diagnosis can lead to better management outcomes.

Not reported in abstract.

summary

B

grade

Monitoring blood free carnitine levels may help in understanding and managing red blood cell quality in hemodialysis patients.

Higher FC levels were associated with increased OFT slope a (β=0.6090, P=0.036).

summary